LifeMine Therapeutics is reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics to address previously intractable therapeutic challenges. LifeMine’s drug discovery engine enables large-scale genomic search and retrieval of small molecule drug candidates that have a highly specific function. Through its discovery engine and proprietary fungal strain collections, LifeMine has discovered, in genomic space, hundreds of potentially high-impact drug candidates relevant to targets across all major disease areas, and has an initial focus on highly impactful precision medicines in oncology and immune modulation. The Company was founded in 2017 by renowned entrepreneur/scientists Gregory Verdine, Ph.D. and Richard Klausner, M.D., and entrepreneur/company-builder WeiQing Zhou, M.B.A. Headquartered in Cambridge, MA, and with a second site at Gloucester Harbor, MA, LifeMine has raised more than $120 million from leading life science investors.
Location: United States
Employees: 51-200
Total raised: $543M
Founded date: 2016
Investors 5
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | 6 Dimensio... | 6dimension... |
| - | MRL Ventur... | mrlv.com |
| - | GV | gv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 19.08.2026 | Series E | $263M | ARCH Ventu... |
| 15.04.2022 | Series C | $175M | - |
| 07.01.2021 | Series B | $50M | - |
| 19.09.2017 | Series A | $55M | ARCH Ventu... |
Mentions in press and media 17
| Date | Title | Description |
| 25.08.2026 | LifeMine Therapeutics Secures Landmark Funding, Reshaping Transplant Medicine | LifeMine Therapeutics secured $263 million. This landmark funding fuels a revolution in organ transplant medicine. The company's lead asset, LIFE-001, offers a next-generation approach. It targets rejection without severe toxicities. Tradit... |
| 19.08.2026 | LifeMine Therapeutics Secures $263M Series D & E | WATERTOWN, MA, LifeMine Therapeutics, a clinical-stage biopharmaceutical company, announced $263 million in financing. >> Click here for more funding data on LifeMine Therapeutics >> To export LifeMine Therapeutics funding data... |
| 07.08.2026 | LifeMine Therapeutics Raises $263M in Funding | LifeMine Therapeutics Inc., a Watertown, MA-based clinical-stage biopharmaceutical company leveraging digital genomics research technology, has raised $263M in funding. The round included a $188M Series E financing led by Milky Way Investme... |
| 06.08.2026 | ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E | Last year, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking off the cobwebs thanks in part to substantial investments... |
| 06.08.2026 | Venture Capital & Startup Funding Roundup, August 6, 2026: Bessemer Venture Partners, Gates Frontier, General Atlantic, Google Ventures, Gradient Ventures, Menlo Ventures, Y Combinator & More | The sprint of venture rounds today underscores a clear theme: autonomy and AI are pulling massive capital — both in the physical world and online. In defense and logistics, startups like Hadrian and Moove drew eye-popping checks ($1.37 bill... |
| 06.08.2026 | LifeMine Therapeutics Raises $263 Million To Advance LIFE-001 For Organ Transplantation | LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of LIFE-001 and advance its broader pipeline of transplantation and immunology therapies. The financing includes an oversubscribed $188 milli... |
| 23.03.2022 | LifeMine Therapeutics Snags $175M in Series C | CAMBRIDGE, MA, LifeMine Therapeutics, a biopharmaceutical company, announced the completion of a $175M Series C financing led by Fidelity Management & Research Company. >> Click here for more funding data on LifeMine Therapeuti... |
| 07.01.2021 | LifeMine Therapeutics Announces $50 Million Series B Financing | LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading l... |
| 07.01.2021 | LifeMine Therapeutics Raises $50 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 millio... |
| 16.05.2018 | FogPharma Secures $66 Million Series B Financing | FogPharma today announced the closing of a $66 millionSeries B financing. The round was led by 6 Dimensions Capital, with participation by additional new investors, including GV (formerly Google Ventures), Blue Pool Capital, Horizons Ventur... |
Show more